首页|不同血液净化方式对维持性血液透析患者β2-MG、CRP、SCr、UA水平的影响

不同血液净化方式对维持性血液透析患者β2-MG、CRP、SCr、UA水平的影响

扫码查看
目的 分析不同血液净化方式对维持性血液透析患者β2-MG、CRP、SCr、UA水平的影响.方法 选取2021年11月至2022年11月秦皇岛中西医结合医院收治的维持性血液透析患者90例,采用随机数字表法分为HD组、LD+HDF组以及HD+HDF组,各30例.比较三组观察指标.结果 治疗6个月后,与HD组、LD+HDF组比较,HD+HDF组的临床总有效率相对更高,差异有统计学意义(P<0.05).与治疗前比较,治疗6个月后三组血液β2-MG、CRP、ESR、血清UA、SCr、Hcy、PTH、AGEs水平、VAS评分均降低,与HD组、LD+HDF组相比,HD+HDF组相对较低;血清BUN水平则均升高,且与HD组、LD+HDF组相比,HD+HDF组相对较高,差异有统计学意义(P<0.05).结论 应用于HD联合HDF能够改善维持性血液透析患者的肾功能,降低患者的炎症反应及毒素指标水平,缓解患者的皮肤瘙痒情况,血液净化效果良好.
Effects of different blood purification methods on β2-MG,CRP,SCr and UA levels in maintenance hemodialysis patients
Objective To analyze the effects of different blood purification methods on the levels of β2-MG,CRP,SCr and UA in maintenance hemodialysis patients.Methods From November 2021 to November 2022,90 patients with maintenance hemodialysis at our hospital were randomly divided into three groups:HD group,LD+HDF group and HD+HDF group with 30 cases in each group.The observational indexes of the three groups were compared.Results After 6 months of treatment,the LD+HDF group had a significant higher total clinical effective rate compared to the HD group,with statistical significance (P<0.05).Compared to before treatment,the levels of blood β2-MG,CRP,ESR,serum UA,SCr,Hcy,PTH,AGEs,and score of VAS in the three groups decreased after 6 months of treatment.In contrast,levels of serum BUN increased in the HD+HDF group compared to the HD group,with statistical significance (P<0.05).Conclusion The application of HD combined with HDF can improve the renal function of maintenance hemodialysis patients.It also helps reduce the inflammatory reaction and toxin index levels in patients and relieving the skin itching.This combination has shown to have a good blood purification effect.

HemodialysisBlood purificationβ2 microglobulinC-reactive proteinCreatinineUric acid

潘红杰、张宇、盖银玲、胡伟南

展开 >

秦皇岛中西医结合医院肾病科,河北,秦皇岛 066002

秦皇岛中西医结合医院血液净化科,河北,秦皇岛 066002

血液透析 血液净化 β2微球蛋白 C反应蛋白 肌酐 尿酸

秦皇岛市市级科学技术研究与发展计划自筹经费项目

202301A045

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(7)